Discovery of N-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment
| Autor: | Huan He, Xin Xu, Anmian Zhang, Baohui Qi, Guobiao Zhou, Xiaobing Wan, Tao Chen, Xupeng Yue, Ying Yang, Junming Li, Guowei Gong, Yun Hu |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Pharmacology
0303 health sciences Cabozantinib 010405 organic chemistry Kinase medicine.drug_class Organic Chemistry General Medicine 01 natural sciences Tyrosine-kinase inhibitor 0104 chemical sciences 03 medical and health sciences chemistry.chemical_compound chemistry Drug Discovery Cancer cell medicine Cytotoxicity Lead compound Tyrosine kinase Protein kinase B 030304 developmental biology |
| Zdroj: | European Journal of Medicinal Chemistry. 163:10-27 |
| ISSN: | 0223-5234 |
| Popis: | A series of 21 novel N1-(2-aryl-1,3-thiazolidin-4-one)-N3-aryl urea derivatives based on the previously identified lead compound I were synthesized and biologically characterized. The most promising compound 19a was identified as a multi-tyrosine kinase inhibitor, including c-Met, Ron, c-Kit, AXL and IGF-1R, etc. The results of real-time live-cell imaging indicated that compound 19a showed improved cytotoxicity and anti-proliferative activity against HT-29 cancer cells in a time- and dose-dependent manner, with an efficacy that was significantly greater than Cabozantinib. Flow cytometry and western blot analysis demonstrated the fact that anticancer activity was closely related with cancer cell apoptosis and the blockade of the phosphorylation of c-Met and its downstream signaling ERK and Akt. Furthermore, compound 19a also displayed slightly stronger effects on HT-29 cancer cells migration than that of Cabozantinib. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect